GlassScriptPhysician profile
Megan E Collett
NPI 1134580145
$13,402.31
in general payments reported to CMS, 2019-2025
59 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $2,317 · 2023: $1,992 · 2024: $5,498 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,966 · Consulting Fee: $2,585 · Education: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,965.64 |
| Consulting Fee | $2,585.00 |
| Education | $481.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $3,573.69 | 2021-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $2,534.30 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $693.98 | 2021-2025 | Ultomiris, Soliris |
| Biogen, INC. | $519.43 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Pfizer INC. | $480.20 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $449.43 | 2021-2025 | |
| Lilly USA, LLC | $400.97 | 2022-2025 | Kisunla, Emgality, Amyvid |
| Janssen Pharmaceuticals, INC | $372.08 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $278.06 | 2021-2025 | Austedo Xr, Austedo |
| Eisai INC. | $265.61 | 2021-2025 | |
| Ucb, INC. | $225.31 | 2022-2025 | Rystiggo |
| Celgene Corporation | $213.14 | 2021-2025 | Zeposia |
| Alnylam Pharmaceuticals INC. | $203.84 | 2022-2025 | Onpattro, Givlaari |
| Merz Pharmaceuticals, LLC | $187.53 | 2022-2024 | Xeomin, Inbrija |
| Argenx US, INC. | $172.55 | 2022-2025 | Vyvgart |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142.19 | 2021-2025 | Uplizna |
| Sk Life Science, INC. | $137.01 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $132.39 | 2022-2025 | Nuplazid, Daybue |
| Csl Behring | $128.89 | 2022-2025 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $126.40 | 2023-2025 | Fycompa |
| Tg Therapeutics, INC. | $124.85 | 2023-2025 | |
| Lundbeck LLC | $110.84 | 2023-2025 | Vyepti, Rexulti |
| Boston Scientific Corporation | $109.76 | 2022-2025 | Cds - Mct/Cem Monitoring, Vercise, General - Dbs |
| Takeda Pharmaceuticals U.S.A., INC. | $109.65 | 2024-2025 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $108.66 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $103.74 | 2022-2025 | Rytary, Lyvispah, Crexont |
| Neurelis, INC. | $95.33 | 2022-2025 | Valtoco |
| Livanova USA, INC. | $92.20 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $85.01 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $84.57 | 2024-2025 | Ponvory |
| Grifols USA, LLC | $82.66 | 2022-2025 | Gamunex-C |
| Supernus Pharmaceuticals, INC. | $74.50 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $69.68 | 2022-2025 | Ongentys, Ingrezza |
| Ipsen Biopharmaceuticals, INC | $62.29 | 2022-2025 | Dysport |
| Sumitomo Pharma America, INC. | $60.93 | 2023-2024 | Aptiom |
| Sunovion Pharmaceuticals INC. | $59.52 | 2021-2022 | |
| Janssen Biotech, INC. | $56.68 | 2025 | |
| Octapharma USA, INC. | $53.83 | 2022-2025 | Panzyga |
| Azurity Pharmaceuticals, INC. | $49.74 | 2023-2025 | Horizant, Horizant |
| Allergan, INC. | $46.47 | 2021-2022 | |
| Acorda Therapeutics, INC | $42.32 | 2022-2024 | Ampyra, Inbrija |
| Jazz Pharmaceuticals INC. | $41.14 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.81 | 2022 | |
| Tanabe Pharma America, INC. | $38.40 | 2024 | |
| Tonix Medicines, INC. | $37.50 | 2024 | Zembrace Symtouch |
| Banner Life Sciences, LLC | $34.98 | 2022 | |
| Upsher-Smith Laboratories LLC | $32.80 | 2022-2023 | |
| Avion Pharmaceuticals | $31.22 | 2022 | |
| Genzyme Corporation | $29.87 | 2025 | |
| Almatica Pharma LLC | $24.64 | 2023 | Gralise |
| Scilex Pharmaceuticals INC. | $21.57 | 2023 | Ztlido |
| Harmony Biosciences LLC | $21.44 | 2025 | |
| Globus Medical, INC. | $21.42 | 2025 | Senza |
| Axsome Therapeutics, INC. | $20.18 | 2025 | Symbravo |
| Cala Health, INC. | $19.77 | 2025 | Cala Kiq |
| Aucta Pharmaceuticals, INC. | $17.95 | 2025 | Motpoly Xr |
| Avanir Pharmaceuticals, INC. | $17.44 | 2021 | |
| Grt US Holding, INC. | $16.83 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Collett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.